PortfoliosLab logoPortfoliosLab logo

Documentation

Upgrade your plan

Parabilis Medicines, Inc. (PBLS) Sharpe Ratio

Equity · Currency in USD · Last updated Jul 25, 2026

Parabilis Medicines, Inc. is a clinical-stage biopharmaceutical company developing stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, led by FOG-001, a TCF-blocking beta-catenin inhibitor for cancer treatment. The company was formerly known as FogPharma, was founded in 2015, and is based in Cambridge, Massachusetts. It completed its initial public offering on the Nasdaq Global Select Market in June 2026.

Sharpe ratio is not yet available for PBLS. This metric requires at least 12 months of historical daily returns to calculate. Check back once this data is available.

How it compares to other similar stocks

The table compares Parabilis Medicines, Inc.'s Sharpe Ratio with other stocks in the Biotechnology industry across multiple time periods, showing how PBLS's risk-adjusted performance compares to industry peers.

Data shows 1-, 5-, and 10-year periods, plus each stock's all-time average, as of Jul 25, 2026.

SymbolName1Y Sharpe Ratio5Y Sharpe Ratio10Y Sharpe RatioAll Time Sharpe Ratio
RVMDWRevolution Medicines Inc. Warrant15.75
ERASErasca, Inc.9.79
CLYMClimb Bio Inc7.85
STTKShattuck Labs, Inc.7.44
DRTSWAlpha Tau Medical Ltd. Warrant7.26
ORKAOruka Therapeutics, Inc7.14
SYRESpyre Therapeutics Inc.6.97
ARWRArrowhead Pharmaceuticals, Inc.6.54
SLGLSol-Gel Technologies Ltd.6.42
RVMDRevolution Medicines, Inc.6.12
PBLSParabilis Medicines, Inc.—

S&P 500 Index

How to choose period

Historical Sharpe Ratio

The chart shows PBLS's rolling Sharpe ratio over time compared to your chosen benchmark. Rising trends indicate improving returns relative to total volatility, while declining trends may signal deteriorating risk-adjusted performance or increased volatility. Use multiple timeframes to distinguish short-term fluctuations from long-term patterns.

Identify market cycles by observing when PBLS consistently outperforms (line above benchmark), underperforms (below benchmark), or aligns with the benchmark.

Loading charts...

Sharpe Ratio Calculator

How does PBLS fit in your portfolio?

Add your other holdings to see your portfolio's Sharpe Ratio and find out.

Analyze Your Portfolio